Expression of TWEAK in normal human skin, dermatitis and epidermal neoplasms: Association with proliferation and differentiation of keratinocytes

Journal of Cutaneous Pathology

Volumn 38, Issue 10, 2011, Pages 780-789

  Peternel, Sandra ^a   Manestar Blažić, Teo ^a   Brajac, Ines ^a   Prpić Massari, Larisa ^a   Kaštelan, Marija ^a  

^a UNIVERSITY OF RIJEKA   (Croatia)

Author keywords

discoid lupus erythematosus; lichen planus; psoriasis; skin cancer; tumor necrosis factor like weak inducer of apoptosis; TWEAK

Indexed keywords

TNFSF12 PROTEIN, HUMAN; TUMOR MARKER; TUMOR NECROSIS FACTOR;

ARTICLE; CELL PROLIFERATION; CELL TRANSFORMATION; DERMATITIS; ENZYME IMMUNOASSAY; HUMAN; KERATINOCYTE; METABOLISM; PATHOLOGY; SKIN; SKIN TUMOR; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DERMATITIS; HUMANS; IMMUNOENZYME TECHNIQUES; KERATINOCYTES; SKIN; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTORS;

EID: 80052269735     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2011.01762.x     Document Type: Article

References (49)

1. Aggarwal BB., Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003; 3: 745
2. Gaur U, Aggarwal BB., Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol 2003; 66: 1403
3. Chicheportiche Y, Bourdon PR, Xu H, et al,. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997; 272: 32401
4. Winkles JA., The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008; 7: 411
5. Jakubowski A, Ambrose C, Parr M, et al., TWEAK induces liver progenitor cell proliferation. J Clin Invest 2005; 115: 2330
6. Sugito T, Mineshiba F, Zheng C, Cotrim AP, Goldsmith CM, Baum BJ., Transient TWEAK overexpression leads to a general salivary epithelial cell proliferation. Oral Dis 2009; 15: 76
7. Desplat-Jégo S, Varriale S, Creidy R, et al., TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity. J Neuroimmunol 2002; 133: 116
8. Gao HX, Campbell SR, Burkly LC, et al., TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells. Cytokine 2009; 46: 24
9. Novoyatleva T, Diehl F, van Amerongen MJ, et al., TWEAK is a positive regulator of cardiomyocyte proliferation. Cardiovasc Res 2010; 85: 681
10. Girgenrath M, Weng S, Kostek CA, et al., TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J 2006; 25: 5826
11. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS., TWEAKing tissue remodelling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 2007; 40: 1
12. Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA, Wiley SR., TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 1999; 274: 8455
13. Donohue PJ, Richards CM, Brown SA, et al., TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol 2003; 23: 594
14. Chicheportiche Y, Chicheportiche R, Sizing I, et al., Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res 2002; 4: 126
15. Jin L, Nakao A, Nakayama M, et al., Induction of RANTES by TWEAK/Fn14 interaction in human keratinocytes. J Invest Dermatol 2004; 122: 1175
16. Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Matsuo T., Proinflammatory effects of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) on human gingival fibroblasts. Clin Exp Immunol 2006; 146: 540
17. Kang S, Yang C, Luo R., Induction of CCL2 by siMAML1 through upregulation of TweakR in melanoma cells. Biochem Biophys Res Commun 2008; 372: 69
18. Perper SJ, Browning B, Burkly LC, et al., TWEAK is a novel arthritogenic mediator. J Immunol 2006; 177: 2610
19. Park MC, Chung SJ, Park YB, Lee SK., Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis. Scand J Rheumatol 2008; 37: 173
20. Leng RX, Pan HF, Qin WZ, et al., TWEAK as a target for therapy in systemic lupus erythematosus. Mol Biol Rep 2011; 38: 587
21. Ortiz A, Sanz AB, Muñoz-García B, et al., Considering TWEAK as a target for therapy in renal and vascular injury. Cytokine Growth Factor Rev 2009; 20: 251
22. Vince JR, Silke J., TWEAK shall inherit the earth. Cell Death Differ 2006; 13: 1842
23. Michaelson JS, Burkly LC., Therapeutic targeting of TWEAK/Fnl4 in cancer: exploiting the intrinsic tumor cell killing capacity of the pathway. Results Probl Cell Differ 2009; 49: 145
24. Kamijo S, Nakajima A, Kamata K, Kurosawa H, Yagita H, Okumura K., Involvement of TWEAK/Fn14 interaction in the synovial inflammation of RA. Rheumatology (Oxford) 2008; 47: 442
25. Tiller G, Fischer-Posovszky P, Laumen H, et al., Effects of TWEAK (TNF superfamily member 12) on differentiation, metabolism, and secretory function of human primary preadipocytes and adipocytes. Endocrinology 2009; 150: 5373
26. Vincent C, Findlay DM, Welldon KJ, et al., Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res 2009; 24: 1434
27. Dogra C, Changotra H, Mohan S, Kumar A., Tumor necrosis factor-like weak inducer of apoptosis inhibits skeletal myogenesis through sustained activation of nuclear factor-kappaB and degradation of MyoD protein. J Biol Chem 2006; 281: 10327
28. Hamill CA, Michaelson JS, Hahm K, Burkly LC, Kessler JA., Age-dependent effects of TWEAK/Fn14 receptor activation on neural progenitor cells. J Neurosci Res 2007; 85: 3535
29. Polek TC, Talpa MZ, Darnay BG, Spivak-Kroizman T., TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptor. J Biol Chem 2003; 278: 32317
30. Jakubowski A, Browning B, Lukashev M, et al., Dual role for TWEAK in angiogenic regulation. J Cell Sci 2002; 115: 267
31. Michaelson JS, Cho S, Browning B, et al., Tweak induces mammary epithelial branching morphogenesis. Oncogene 2005; 24: 2613
32. Schwartz N, Rubinstein T, Burkly LC, et al., Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther 2009; 11: R143
33. Zimmermann M, Koreck A, Meyer N, et al., TNF-like weak inducer of apoptosis (TWEAK) and TNF-α cooperate in the induction of keratinocyte apoptosis. J Allergy Clin Immunol 2011; 127: 200
34. Blanco-Colio LM, Martín-Ventura JL, Muñõz- García B, et al., Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 916
35. Kralisch S, Ziegelmeier M, Bachmann A, et al., Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis 2008; 199: 440
36. Bielecki M, Kowal K, Lapinska A, et al., Diminished production of TWEAK by the peripheral blood mononuclear cells is associated with vascular involvement in patients with systemic sclerosis. Folia Histochem Cytobiol 2009; 47: 465
37. Chicheportiche Y, Fossati-Jimack L, Moll S, Ibnou-Zekri N, Izui S., Down-regulated expression of TWEAK mRNA in acute and chronic inflammatory pathologies. Biochem Biophys Res Commun 2000; 279: 162
38. de Jong EM, van Erp PE, Ruiter DJ, van de Kerkhof PC., Immunohistochemical detection of proliferation and differentiation in discoid lupus erythematosus. J Am Acad Dermatol 1991; 25: 1032
39. Bovenschen HJ, Seyger MM, Van de Kerkhof PC., Plaque psoriasis vs. atopic dermatitis and lichen planus: a comparison for lesional T-cell subsets, epidermal proliferation and differentiation. Br J Dermatol 2005; 153: 72
40. Mortier L, Marchetti P, Delaporte E, et al., Progression of actinic keratosis to squamous cell carcinoma of the skin correlates with deletion of the 9p21 region encoding the p16(INK4a) tumor suppressor. Cancer Lett 2002; 176: 205
41. Kanellou P, Zaravinos A, Zioga M, et al., Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis. Cancer Lett 2008; 264: 145
42. Pacifico A, Goldberg LH, Peris K, Chimenti S, Leone G, Ananthaswamy HN., Loss of CDKN2A and p14ARF expression occurs frequently in human nonmelanoma skin cancers. Br J Dermatol 2008; 158: 291
43. Bachmann F, Buechner SA, Wernli M, Strebel S, Erb P., Ultraviolet light downregulates CD95 ligand and TRAIL receptor expression facilitating actinic keratosis and squamous cell carcinoma formation. J Invest Dermatol 2001; 117: 59
44. Ständer S, Schwarz T., Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is expressed in normal skin and cutaneous inflammatory diseases, but not in chronically UV-exposed skin and non-melanoma skin cancer. Am J Dermatopathol 2005; 27: 116
45. Ouhtit A, Gorny A, Muller HK, Hill LL, Owen-Schaub L, Ananthaswamy HN., Loss of Fas-ligand expression in mouse keratinocytes during UV carcinogenesis. Am J Pathol 2000; 157: 1975
46. Peternel S, PrpiÄ-Massari L, Manestar-BlažiÄ T, Brajac I, Kaštelan M., Increased expression of TRAIL and its death receptors DR4 and DR5 in plaque psoriasis. Arch Dermatol Res 2011; DOI: 10.1007/s00403-011- 1125-0 [Epub ahead of print]
47. Gilhar A, Yaniv R, Assy B, Serafimovich S, Ullmann Y, Kalish RS., Fas pulls the trigger on psoriasis. Am J Pathol 2006; 168: 170
48. Vassina E, Leverkus M, Yousefi S, Braathen LR, Simon HU, Simon D., Increased expression and a potential anti-inflammatory role of TRAIL in atopic dermatitis. J Invest Dermatol 2005; 125: 746
49. Farley SM, Dotson AD, Purdy DE, et al., Fas ligand elicits a caspase-independent proinflammatory response in human keratinocytes: implications for dermatitis. J Invest Dermatol 2006; 126: 2438